Loading...
skip to Main Content

In today’s #readoftheweek📚, the authors use a Markov decision process model to demonstrate that earlier transplantation of patients with ACLF-3 maximizes overall survival.

👉Read here this @JHEP_Reports article by @VinaySundaramMD @RajivJalan1 et al. http://bit.ly/3DvxIEd

💻Join us today for a new episode of the #EASLstudio.

➡️LIVE, from 18:00 CET, our experts will discuss the key goals of the EASL-@TheLancet Liver Commission.

@EASLedu @JHepatology @aelsharkawy75 @AleksanderKrag @tomhemmingk

https://easl.eu/easl-studio/

Webcast description

This episode of EASL’s webcast series on COVID-19 and the liver examines the impact of the virus on patients with obesity and fatty liver disease. The panel of experts comprises Professor Sven Francque, Professor Nalu Navarro-Alvarez, Professor Luca Busetto and Professor Carolyn Bramante. Professor Busetto begins by reviewing prevalence data on COVID-19 in people with obesity or metabolic syndrome, drawing from Italian and global experiences, and describes the biological mechanisms behind increased COVID-19 severity in these populations. Professor Bramante reports on research linking fatty liver disease with severe COVID-19 and the potential for some medications to be protective against hospitalization in these patients. Professor Navarro-Alvarez describes the mechanisms behind the elevated risk of COVID-19 and the impact of metabolic syndrome. The panel addresses several aspects including the importance of visceral adiposity and systemic inflammation.

Moderator: Prof. Sven Francque
Panel:
• Prof. Luca Busetto
• Prof. Carolyn Bramante
• Prof. Nalu Navarro-Alvarez

Learning objectives

  • Learn about the prevalence of COVID-19 in people with obesity or fatty liver disease
  • Understand the mechanisms behind the elevated risk of COVID-19 and the impact of metabolic syndrome
  • Learn about medications that might prevent hospitalization of patient with fatty liver disease and severe COVID-19
  • Learn how the visceral adiposity and systemic inflammation impact COVID-19 severity

Target audience

  • Hepatologists
  • General practitioners
  • Health care professionals
  • Clinical researchers and scientists

In today’s #readoftheweek📚, the authors use a Markov decision process model to demonstrate that earlier transplantation of patients with ACLF-3 maximizes overall survival.

👉Read here this @JHEP_Reports article by @VinaySundaramMD @RajivJalan1 et al. http://bit.ly/3DvxIEd

💻Join us today for a new episode of the #EASLstudio.

➡️LIVE, from 18:00 CET, our experts will discuss the key goals of the EASL-@TheLancet Liver Commission.

@EASLedu @JHepatology @aelsharkawy75 @AleksanderKrag @tomhemmingk

https://easl.eu/easl-studio/

Back To Top